Home/Pipeline/Amycretin (Subcutaneous)

Amycretin (Subcutaneous)

Obesity

Phase 2Active

Key Facts

Indication

Obesity

Phase

Phase 2

Status

Active

Company

Novo Nordisk

About Novo Nordisk

Novo Nordisk's mission is to defeat diabetes and other serious chronic diseases through innovative biopharmaceutical solutions. The company has achieved transformative success with its GLP-1-based therapies, Ozempic® and Wegovy®, catalyzing a new era in metabolic care and generating massive commercial growth. Its strategy is built on expanding the clinical utility of its core platforms, advancing a deep pipeline of next-generation multi-agonists and novel modalities, and scaling manufacturing to meet global demand. Recent milestones include the US approval of the first once-weekly basal insulin, Awiqli®, and promising Phase 2 data for a triple agonist.

View full company profile

Therapeutic Areas

Diabetes Obesity Rare Blood & Endocrine Disorders Cardiovascular Disease Chronic Kidney Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active